CALCA and psoriasis: Similarly, oral administration of B. breve CCFM683 (dose >108.42 CFU/day) significantly improved psoriasis in mice through multifaceted mechanisms: reducing inflammatory cytokines, regulating KC proliferation/differentiation, protecting the epidermal barrier by increasing filaggrin and loricrin, and promoting BA production.